Demographic, clinical, and epidemiologic characteristics of persons under investigation for Coronavirus Disease 2019-United States, January 17-February 29, 2020.
Adolescent
Adult
Aged
Aged, 80 and over
COVID-19
/ diagnosis
COVID-19 Nucleic Acid Testing
Centers for Disease Control and Prevention, U.S.
Child
Child, Preschool
Cohort Studies
Epidemiological Monitoring
Female
Humans
Male
Middle Aged
Public Health
SARS-CoV-2
/ isolation & purification
Travel
Travel-Related Illness
United States
/ epidemiology
Young Adult
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
16
09
2020
accepted:
28
03
2021
entrez:
15
4
2021
pubmed:
16
4
2021
medline:
30
4
2021
Statut:
epublish
Résumé
The Coronavirus Disease 2019 (COVID-19) pandemic, caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), evolved rapidly in the United States. This report describes the demographic, clinical, and epidemiologic characteristics of 544 U.S. persons under investigation (PUI) for COVID-19 with complete SARS-CoV-2 testing in the beginning stages of the pandemic from January 17 through February 29, 2020. In this surveillance cohort, the U.S. Centers for Disease Control and Prevention (CDC) provided consultation to public health and healthcare professionals to identify PUI for SARS-CoV-2 testing by quantitative real-time reverse-transcription PCR. Demographic, clinical, and epidemiologic characteristics of PUI were reported by public health and healthcare professionals during consultation with on-call CDC clinicians and subsequent submission of a CDC PUI Report Form. Characteristics of laboratory-negative and laboratory-positive persons were summarized as proportions for the period of January 17-February 29, and characteristics of all PUI were compared before and after February 12 using prevalence ratios. A total of 36 PUI tested positive for SARS-CoV-2 and were classified as confirmed cases. Confirmed cases and PUI testing negative for SARS-CoV-2 had similar demographic, clinical, and epidemiologic characteristics. Consistent with changes in PUI evaluation criteria, 88% (13/15) of confirmed cases detected before February 12, 2020, reported travel from China. After February 12, 57% (12/21) of confirmed cases reported no known travel- or contact-related exposures. These findings can inform preparedness for future pandemics, including capacity for rapid expansion of novel diagnostic tests to accommodate broad surveillance strategies to assess community transmission, including potential contributions from asymptomatic and presymptomatic infections.
Sections du résumé
BACKGROUND
The Coronavirus Disease 2019 (COVID-19) pandemic, caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), evolved rapidly in the United States. This report describes the demographic, clinical, and epidemiologic characteristics of 544 U.S. persons under investigation (PUI) for COVID-19 with complete SARS-CoV-2 testing in the beginning stages of the pandemic from January 17 through February 29, 2020.
METHODS
In this surveillance cohort, the U.S. Centers for Disease Control and Prevention (CDC) provided consultation to public health and healthcare professionals to identify PUI for SARS-CoV-2 testing by quantitative real-time reverse-transcription PCR. Demographic, clinical, and epidemiologic characteristics of PUI were reported by public health and healthcare professionals during consultation with on-call CDC clinicians and subsequent submission of a CDC PUI Report Form. Characteristics of laboratory-negative and laboratory-positive persons were summarized as proportions for the period of January 17-February 29, and characteristics of all PUI were compared before and after February 12 using prevalence ratios.
RESULTS
A total of 36 PUI tested positive for SARS-CoV-2 and were classified as confirmed cases. Confirmed cases and PUI testing negative for SARS-CoV-2 had similar demographic, clinical, and epidemiologic characteristics. Consistent with changes in PUI evaluation criteria, 88% (13/15) of confirmed cases detected before February 12, 2020, reported travel from China. After February 12, 57% (12/21) of confirmed cases reported no known travel- or contact-related exposures.
CONCLUSIONS
These findings can inform preparedness for future pandemics, including capacity for rapid expansion of novel diagnostic tests to accommodate broad surveillance strategies to assess community transmission, including potential contributions from asymptomatic and presymptomatic infections.
Identifiants
pubmed: 33857209
doi: 10.1371/journal.pone.0249901
pii: PONE-D-20-29226
pmc: PMC8049245
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0249901Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
MMWR Morb Mortal Wkly Rep. 2020 Feb 28;69(8):216-219
pubmed: 32106216
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
MMWR Morb Mortal Wkly Rep. 2020 Apr 10;69(14):422-426
pubmed: 32271728
MMWR Morb Mortal Wkly Rep. 2020 May 08;69(18):551-556
pubmed: 32379733
MMWR Morb Mortal Wkly Rep. 2020 Apr 17;69(15):477-481
pubmed: 32298247
Lancet. 2020 Apr 4;395(10230):1137-1144
pubmed: 32178768
Emerg Infect Dis. 2020 Aug;26(8):
pubmed: 32396505
MMWR Morb Mortal Wkly Rep. 2020 Mar 06;69(9):245-246
pubmed: 32134909
MMWR Morb Mortal Wkly Rep. 2020 Apr 17;69(15):472-476
pubmed: 32298249
JAMA. 2020 Apr 7;323(13):1313-1314
pubmed: 32058570
MMWR Morb Mortal Wkly Rep. 2020 Mar 27;69(12):347-352
pubmed: 32214086
MMWR Morb Mortal Wkly Rep. 2020 Jun 05;69(22):680-684
pubmed: 32497028
MMWR Morb Mortal Wkly Rep. 2020 Feb 14;69(6):166-170
pubmed: 32053579
Allergy. 2020 Jul;75(7):1730-1741
pubmed: 32077115
Lancet Public Health. 2020 Sep;5(9):e475-e483
pubmed: 32745512